Contineum Therapeutics, Inc. Class A Common Stock
CTNMNASDAQHealthcare● Active
$11.50
+$0.01(+0.09%)
Market Cap$429943301
P/E Ratio—
52W High$16.33
52W Low$3.57
Contineum Therapeutics, Inc. Class A Common Stock (CTNM) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · CTNM · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.00B | $0.00B | $0.05B | $0.00B | $0.00B |
| Cost of Revenue | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Gross Profit | $0.00B | ($0.00B) | $0.05B | $0.00B | $0.00B |
| Gross Margin %(computed) | — | — | 100.00% | — | — |
| Operating Expenses | |||||
| R&D Expenses | $0.05B | $0.04B | $0.03B | $0.02B | $0.02B |
| G&A Expenses | $0.02B | $0.01B | $0.01B | $0.01B | $0.01B |
| Total Operating Expenses | $0.07B | $0.05B | $0.07B | $0.02B | $0.03B |
| Operating Income | ($0.07B) | ($0.05B) | ($0.02B) | ($0.02B) | ($0.03B) |
| Operating Margin %(computed) | — | — | -32.15% | — | — |
| Interest Income | $0.01B | $0.01B | $0.00B | $0.00B | $0.00B |
| Interest Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Income Before Tax | ($0.06B) | ($0.04B) | $0.02B | ($0.02B) | ($0.03B) |
| Income Tax Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Net Income | ($0.06B) | ($0.04B) | $0.02B | ($0.02B) | ($0.03B) |
| Net Margin %(computed) | — | — | 45.44% | — | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-2.17 | $-1.63 | $0.13 | $-0.97 | $-1.15 |
| Wtd Avg Shares | 0.03B | 0.03B | 0.03B | 0.03B | 0.03B |
| EBITDA | ($0.07B) | ($0.04B) | $0.02B | ($0.02B) | ($0.03B) |
| EBITDA Margin %(computed) | — | — | 47.15% | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · B
Explore more Contineum Therapeutics, Inc. Class A Common Stock data
About Contineum Therapeutics, Inc. Class A Common Stock (CTNM) Income Statement
Contineum Therapeutics, Inc. Class A Common Stock (CTNM) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, CTNM reported revenue of $0.00B, gross profit of $0.00B (gross margin —), and net income of ($0.06B) — a net profit margin of —.
Frequently asked questions
CTNM · 4 questionsContineum Therapeutics, Inc. Class A Common Stock (CTNM) reported revenue of $0.00B for 2025, down —% year-over-year.
CTNM revenueCTNM salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08